Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2859479 | 0.98 | MEN1 (0.50) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL2954307 | 0.69 | MEN1 (0.44) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL18508556 | 0.65 | ALDH1A1 (0.36) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL821037 | 0.65 | MEN1 (1.00) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| Eprenetapopt SCHEMBL21636035 | 0.61 | MEN1 (0.72) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL11611520 | 0.59 | PDK2 (0.32) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL21417032 | 0.58 | ALDH1A1 (0.38) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL3053776 | 0.58 | PIK3CD (0.33) | — | |
| SCHEMBL21063813 | 0.56 | CHRNA7 (0.38) | — | |
| SCHEMBL10834624 | 0.55 | TP53 (0.30) | MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3724188-B1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20210163471-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS | 2021-06-03 | — | — | US | disclosed |
| EP-3724188-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | Arkuda Therapeutics (US) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019118528-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163471-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | GRN, PRNP, PSEN1 | MEN1 968/4885MAPT 11/4885CYP2C9 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.